World Health Organization, South-East Asia Regional Office
Vol. 21, Week 48, 2017
Published 04 December 2017
Meetings/ Important events:
Regional Working Group Meeting on Immunization, New Delhi, India, 28-30 January 2018
Lessons from the Big Six- Closing the Immunity Gap for Measles Elimination and Rubella/ CRS control, New Delhi, India, 31 January-02
February 2018
Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 04 December 2017)
Case classification (number)
Pending classification
Epidemiologicallyconfirmed
Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na tiona l
ca s es per
l evel per
100,000 pop n
100,000 pop n
Laboratory-confirmed
Discarded non-measles nonrubella cases
Rubel l a
Clinically-confirmed
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
mea s l es
s erum
on
ca s es
i ni tia ted s peci mens
col l ected
w/i n 48
hours of
notifi ca tion
7 677
92
81
6 210
100
100
62
2 576
912
458
218
34
3 479
0
2.42
75
27.40
1.75
221
84
79
166
59
105
46
14
0
0
2
0
160
45
23.26
65
20.35
2.91
DPR Korea
63
100
100
63
100
100
100
0
0
0
0
0
63
0
0.28
0.00
0.00
3
17 145
0
33
5 507
77
86
55
2 626
6 144
0
705
2 004
2 566
3 100
0.22
7.51
2.32
4 351
38
100
2 982
91
74
22
770
0
0
511
0
406
2 664
0.17
3.31
2.20
Maldives
62
97
100
62
100
100
69
1
0
0
1
0
59
1
18.70
60
3.17
3.17
Myanmar
1 655
40
88
1 450
99
100
94
996
179
71
3
0
377
29
0.79
14
26.25
0.06
Nepal
789
26
89
311
76
214
72
51
26
10
15
0
652
35
2.59
55
3.45
0.59
Sri Lanka
203
98
89
177
90
100
62
1
0
18
1
0
183
0
0.96
23
62.00
0.42
Thailand
2 609
30
90
2 236
57
95
58
1 355
5
393
23
0
747
86
1.25
121
100
99
113
100
74
55
0
0
0
3
0
117
1
10.46
34 896
31
61
19 277
86
93
56
8 390
7 266
950
1 482
2 038
8 809
5 961
0.47
Countries
Bangladesh
Bhutan
India
Indonesia
4
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
4
5
38
A lso includes the cases fro m enhanced measles case-based surveillance.
29.27
0.38
0.00
2.68
9.65
2.04
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2016* (data as of 04 December 2017)
Case classification (number)
Indonesia
4
Maldives
Myanmar
Pending classification
Discarded non-measles nonrubella cases
Epidemiologicallyconfirmed
India 3
Reporti ng
% di s tri cts
ra te of
reporti ng a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
non-rubel l a
pop n
pop n
na ti ona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n
Laboratory-confirmed
DPR Korea
Rubel l a
Clinically-confirmed
Bhutan
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Bangladesh
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ecti on
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
Countries
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves ti ga ti ca s es wi th
s erum
on
mea s l es
i ni ti a ted s peci mens
ca s es
col l ected
w/i n 48
hours of
noti fi ca ti on
4 298
94
87
3 732
100
100
92
619
354
96
165
0
3 064
0
1.96
80
6.85
149
63
87
127
59
102
47
10
0
0
0
0
60
79
8.05
55
13.42
0.00
73
100
100
73
100
100
100
0
0
0
0
0
66
7
0.27
0.00
0.00
12.98
7.23
41 593
0
22
9 030
85
83
31
3 646
12 782
0
1 616
7 538
6 997
9 014
0.55
7 999
44
100
4 960
98
86
30
2 824
0
0
1 155
0
2 368
1 652
0.94
11
100
100
11
100
0
0
0
0
0
0
0
11
0
3.22
99
97
194
59
21
10
0
303
0
0
137
102
31
22
0
772
15
11.20
4.58
15
0.00
0.00
0.59
11
5.33
0.19
2.83
56
9.89
0.81
27
62.00
0.42
587
0
86
503
100
1 079
13
82
1
100
Sri Lanka
339
63
86
291
88
100
68
64
0
48
1
0
226
0
1.09
Thailand
1 431
25
87
1 096
61
99
58
695
15
239
7
0
415
60
0.64
122
75
91
111
100
95
63
2
0
11
9
0
100
0
8.25
57 681
15
42
19 935
90
93
46
8 191
13 312
446
2 985
7 538
14 382
10 827
0.77
Nepal
5
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
A lso includes the cases fro m enhanced measles case-based surveillance.
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
5
So me Lab data variables no t available.
3
1.06
46
14.63
0.11
10.73
7.43
11.77
5.64
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
Vol. 21,
Week 48, 2017
Vaccine Preventable Disease Surveillance Bulletin
Page 2
Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2016-2017 (data as of 04 December 2017)
2016 (Onset)
2017 (Onset)
AFP
Surveillance Indicators
1
2
AFP Cases
Compatible
Discarded (Non-polio
AFP)
Total
>90 Days 3
1 437
0
0
2.85
2.85
99
100
1 301
0
0
0
1 209
92
14
2.83
2.63
98
99
0
11
0
0
5.11
5.11
73
100
8
0
0
0
3
5
1
3.51
1.31
88
100
DPR Korea
105
0
0
0
105
0
0
1.83
1.83
98
100
79
0
0
0
48
31
17
1.50
0.91
96
100
Non-Polio AFP Rate
AFP Rate
4
Vaccine Derived
Poliovirus Cases
% with any specimen
% with any specimen
0
0
Pending
% with 2 spec., at least
24 hrs apart, w/in 14
days
Non-Polio AFP Rate
0
0
Wild Poliovirus Cases
AFP Rate
0
11
Bangladesh
Pending
% with 2 spec., at least
24 hrs apart, w/in 14
days
>90 Days 3
1 437
Bhutan
Country
4
Total
Specim en
Discarded (Non-polio
AFP)
1
Compatible
Case Classification
Vaccine Derived
Poliovirus Cases
Specim en
Wild Poliovirus Cases
AFP Rates
Surveillance Indicators
Annualized
AFP Rates 2
AFP Cases
Case Classification
AFP
India
46 500
0
1
15
46 484
0
0
10.60 10.60
87
98
34 984
0
0
9
31 380 3 595 1 238
8.65
7.75
86
98
Indonesia
1 409
0
0
0
1 409
0
0
2.01
86
96
1 236
0
0
1
1 023
1.90
1.58
84
98
2.01
212
97
Maldives
2
0
0
0
2
0
0
2.11
2.11
0
100
5
0
0
0
0
5
4
5.73
0.00
40
100
Myanm ar
466
0
0
0
466
0
0
3.38
3.38
96
100
322
0
0
0
310
12
0
2.59
2.49
97
100
Nepal
455
0
0
0
455
0
0
5.24
5.24
96
100
314
0
0
0
291
23
3
3.92
3.63
98
100
Sri Lanka
65
0
0
0
65
0
0
1.20
1.20
85
98
65
0
0
0
58
7
1
1.30
1.16
86
98
Thailand
246
0
0
0
246
0
0
2.04
2.04
75
98
166
0
0
0
130
36
20
1.56
1.22
66
93
1
2
1
0.70
0.23
33
100
6.90
6.18
86
98
Tim or-Leste
SEAR
10
0
0
0
10
0
0
2.16
2.16
50
80
3
0
0
0
50 706
0
1
15
50 690
0
0
8.38
8.38
87
98
38 483
0
0
10
34 453 4 020 1 396
1
All countries are using the virologic classification scheme.
2
AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).
3
90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.
2016 India: One type 2 VDPV (iVDPV=1)
[a=ambiguous c=circulating i=immunodeficiency]
4
Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2016-2017 (data as of 04 December 2017)
0
0
1
3
0
0
1
0
0
19
0
0
0
0
0
0
0
0
0
0
DPR Korea
NPL, Pyongyong
India
0
0
0
0
0
Vaccine
mixture
NPEV by
PCR
7
days
0
BJMC, Ahmedabad
258
0
78
0
25
0
0
74
80
1
0
0
0
0
222
0
78
0
0
0
0
61
76
7
0
0
0
0
NIV, Bengaluru
225
0
56
0
24
0
0
67
70
6
2
0
0
0
149
0
56
0
0
0
0
35
44
14
0
0
0
0
ERC, Mumbai
172
0
53
0
13
0
0
52
43
11
0
0
0
0
147
0
51
0
0
0
0
43
36
17
0
0
0
0
SGPGI, Lucknow
311
0
56
0
53
0
0
86
66
16
34
0
0
0
288
0
59
0
0
0
0
100
62
25
41
0
1
0
KIPM, Chennai
98
0
26
0
17
1
0
26
28
0
0
0
0
0
48
0
9
0
0
0
0
27
12
0
0
0
0
0
NCDC, Delhi
231
0
47
0
38
0
0
91
52
3
0
0
0
0
203
0
57
0
0
0
0
87
51
8
0
0
0
0
IoS, Kolkatta
113
0
26
0
18
0
0
35
33
0
1
0
0
0
167
0
54
0
0
0
0
39
53
17
3
0
1
0
CRI, Kasauli
35
0
5
0
7
0
0
11
12
0
0
0
0
0
21
0
11
0
0
0
0
6
4
0
0
0
0
0
1 443
0
347
0
195
1
0
442
384
37
37
0
0
0
1 245
0
375
0
0
0
0
398
338
88
44
0
2
0
18
0
9
0
3
0
0
1
5
0
0
0
0
0
2
0
0
0
0
0
0
2
0
0
0
0
0
0
India Total
Bio Farma, Bandung
Indonesia
0
Negative
0
1
Results
pending
NEV
0
0
Vaccine
3
0
Wild
0
0
VDPV
8
1
Vaccine
IPH, Dhaka
NIH, Bangkok
Wild
Bangladesh
Bhutan
Vaccine
7
Days days
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
Wild
Results
pending
AFP cases
referred
for ITD
NEV
Negative
2017
Vaccine
mixture
NPEV by
PCR
Vaccine
Wild
VDPV
Vaccine
Wild
Vaccine
ITD Labs
Wild
Country of
Case
AFP cases
referred
for ITD
2016
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
NIHRD, Jakarta
12
0
4
0
0
0
0
5
3
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
PHL, Surabaya
13
0
2
0
4
0
0
4
3
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
Indonesia Total
43
0
15
0
7
0
0
10
11
0
0
0
0
0
4
0
0
0
0
0
0
3
1
0
0
0
0
0
Myanm ar
NHL, Yangon
7
0
1
0
1
0
0
2
3
0
0
0
0
0
5
0
1
0
0
0
0
3
1
0
0
0
0
0
Nepal
NIH, Bangkok
6
0
2
0
2
0
0
1
1
0
0
0
0
0
5
0
0
0
0
0
0
3
2
0
0
0
0
0
Sri Lanka
MRI, Colombo
1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
Thailand
NIH, Bangkok
4
0
0
0
0
0
0
2
2
0
0
0
0
0
5
0
2
0
0
0
0
3
0
0
0
0
0
0
1 513
0
368
0
206
1
0
459
404
37
37
1
0
0
1 283
0
386
0
0
0
0
416
347
88
44
0
2
0
TOTAL
Published 04 December 2017
Meetings/ Important events:
Regional Working Group Meeting on Immunization, New Delhi, India, 28-30 January 2018
Lessons from the Big Six- Closing the Immunity Gap for Measles Elimination and Rubella/ CRS control, New Delhi, India, 31 January-02
February 2018
Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 04 December 2017)
Case classification (number)
Pending classification
Epidemiologicallyconfirmed
Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na tiona l
ca s es per
l evel per
100,000 pop n
100,000 pop n
Laboratory-confirmed
Discarded non-measles nonrubella cases
Rubel l a
Clinically-confirmed
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
mea s l es
s erum
on
ca s es
i ni tia ted s peci mens
col l ected
w/i n 48
hours of
notifi ca tion
7 677
92
81
6 210
100
100
62
2 576
912
458
218
34
3 479
0
2.42
75
27.40
1.75
221
84
79
166
59
105
46
14
0
0
2
0
160
45
23.26
65
20.35
2.91
DPR Korea
63
100
100
63
100
100
100
0
0
0
0
0
63
0
0.28
0.00
0.00
3
17 145
0
33
5 507
77
86
55
2 626
6 144
0
705
2 004
2 566
3 100
0.22
7.51
2.32
4 351
38
100
2 982
91
74
22
770
0
0
511
0
406
2 664
0.17
3.31
2.20
Maldives
62
97
100
62
100
100
69
1
0
0
1
0
59
1
18.70
60
3.17
3.17
Myanmar
1 655
40
88
1 450
99
100
94
996
179
71
3
0
377
29
0.79
14
26.25
0.06
Nepal
789
26
89
311
76
214
72
51
26
10
15
0
652
35
2.59
55
3.45
0.59
Sri Lanka
203
98
89
177
90
100
62
1
0
18
1
0
183
0
0.96
23
62.00
0.42
Thailand
2 609
30
90
2 236
57
95
58
1 355
5
393
23
0
747
86
1.25
121
100
99
113
100
74
55
0
0
0
3
0
117
1
10.46
34 896
31
61
19 277
86
93
56
8 390
7 266
950
1 482
2 038
8 809
5 961
0.47
Countries
Bangladesh
Bhutan
India
Indonesia
4
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
4
5
38
A lso includes the cases fro m enhanced measles case-based surveillance.
29.27
0.38
0.00
2.68
9.65
2.04
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2016* (data as of 04 December 2017)
Case classification (number)
Indonesia
4
Maldives
Myanmar
Pending classification
Discarded non-measles nonrubella cases
Epidemiologicallyconfirmed
India 3
Reporti ng
% di s tri cts
ra te of
reporti ng a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
non-rubel l a
pop n
pop n
na ti ona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n
Laboratory-confirmed
DPR Korea
Rubel l a
Clinically-confirmed
Bhutan
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Bangladesh
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ecti on
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
Countries
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves ti ga ti ca s es wi th
s erum
on
mea s l es
i ni ti a ted s peci mens
ca s es
col l ected
w/i n 48
hours of
noti fi ca ti on
4 298
94
87
3 732
100
100
92
619
354
96
165
0
3 064
0
1.96
80
6.85
149
63
87
127
59
102
47
10
0
0
0
0
60
79
8.05
55
13.42
0.00
73
100
100
73
100
100
100
0
0
0
0
0
66
7
0.27
0.00
0.00
12.98
7.23
41 593
0
22
9 030
85
83
31
3 646
12 782
0
1 616
7 538
6 997
9 014
0.55
7 999
44
100
4 960
98
86
30
2 824
0
0
1 155
0
2 368
1 652
0.94
11
100
100
11
100
0
0
0
0
0
0
0
11
0
3.22
99
97
194
59
21
10
0
303
0
0
137
102
31
22
0
772
15
11.20
4.58
15
0.00
0.00
0.59
11
5.33
0.19
2.83
56
9.89
0.81
27
62.00
0.42
587
0
86
503
100
1 079
13
82
1
100
Sri Lanka
339
63
86
291
88
100
68
64
0
48
1
0
226
0
1.09
Thailand
1 431
25
87
1 096
61
99
58
695
15
239
7
0
415
60
0.64
122
75
91
111
100
95
63
2
0
11
9
0
100
0
8.25
57 681
15
42
19 935
90
93
46
8 191
13 312
446
2 985
7 538
14 382
10 827
0.77
Nepal
5
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
A lso includes the cases fro m enhanced measles case-based surveillance.
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
5
So me Lab data variables no t available.
3
1.06
46
14.63
0.11
10.73
7.43
11.77
5.64
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
Vol. 21,
Week 48, 2017
Vaccine Preventable Disease Surveillance Bulletin
Page 2
Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2016-2017 (data as of 04 December 2017)
2016 (Onset)
2017 (Onset)
AFP
Surveillance Indicators
1
2
AFP Cases
Compatible
Discarded (Non-polio
AFP)
Total
>90 Days 3
1 437
0
0
2.85
2.85
99
100
1 301
0
0
0
1 209
92
14
2.83
2.63
98
99
0
11
0
0
5.11
5.11
73
100
8
0
0
0
3
5
1
3.51
1.31
88
100
DPR Korea
105
0
0
0
105
0
0
1.83
1.83
98
100
79
0
0
0
48
31
17
1.50
0.91
96
100
Non-Polio AFP Rate
AFP Rate
4
Vaccine Derived
Poliovirus Cases
% with any specimen
% with any specimen
0
0
Pending
% with 2 spec., at least
24 hrs apart, w/in 14
days
Non-Polio AFP Rate
0
0
Wild Poliovirus Cases
AFP Rate
0
11
Bangladesh
Pending
% with 2 spec., at least
24 hrs apart, w/in 14
days
>90 Days 3
1 437
Bhutan
Country
4
Total
Specim en
Discarded (Non-polio
AFP)
1
Compatible
Case Classification
Vaccine Derived
Poliovirus Cases
Specim en
Wild Poliovirus Cases
AFP Rates
Surveillance Indicators
Annualized
AFP Rates 2
AFP Cases
Case Classification
AFP
India
46 500
0
1
15
46 484
0
0
10.60 10.60
87
98
34 984
0
0
9
31 380 3 595 1 238
8.65
7.75
86
98
Indonesia
1 409
0
0
0
1 409
0
0
2.01
86
96
1 236
0
0
1
1 023
1.90
1.58
84
98
2.01
212
97
Maldives
2
0
0
0
2
0
0
2.11
2.11
0
100
5
0
0
0
0
5
4
5.73
0.00
40
100
Myanm ar
466
0
0
0
466
0
0
3.38
3.38
96
100
322
0
0
0
310
12
0
2.59
2.49
97
100
Nepal
455
0
0
0
455
0
0
5.24
5.24
96
100
314
0
0
0
291
23
3
3.92
3.63
98
100
Sri Lanka
65
0
0
0
65
0
0
1.20
1.20
85
98
65
0
0
0
58
7
1
1.30
1.16
86
98
Thailand
246
0
0
0
246
0
0
2.04
2.04
75
98
166
0
0
0
130
36
20
1.56
1.22
66
93
1
2
1
0.70
0.23
33
100
6.90
6.18
86
98
Tim or-Leste
SEAR
10
0
0
0
10
0
0
2.16
2.16
50
80
3
0
0
0
50 706
0
1
15
50 690
0
0
8.38
8.38
87
98
38 483
0
0
10
34 453 4 020 1 396
1
All countries are using the virologic classification scheme.
2
AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).
3
90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.
2016 India: One type 2 VDPV (iVDPV=1)
[a=ambiguous c=circulating i=immunodeficiency]
4
Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2016-2017 (data as of 04 December 2017)
0
0
1
3
0
0
1
0
0
19
0
0
0
0
0
0
0
0
0
0
DPR Korea
NPL, Pyongyong
India
0
0
0
0
0
Vaccine
mixture
NPEV by
PCR
7
days
0
BJMC, Ahmedabad
258
0
78
0
25
0
0
74
80
1
0
0
0
0
222
0
78
0
0
0
0
61
76
7
0
0
0
0
NIV, Bengaluru
225
0
56
0
24
0
0
67
70
6
2
0
0
0
149
0
56
0
0
0
0
35
44
14
0
0
0
0
ERC, Mumbai
172
0
53
0
13
0
0
52
43
11
0
0
0
0
147
0
51
0
0
0
0
43
36
17
0
0
0
0
SGPGI, Lucknow
311
0
56
0
53
0
0
86
66
16
34
0
0
0
288
0
59
0
0
0
0
100
62
25
41
0
1
0
KIPM, Chennai
98
0
26
0
17
1
0
26
28
0
0
0
0
0
48
0
9
0
0
0
0
27
12
0
0
0
0
0
NCDC, Delhi
231
0
47
0
38
0
0
91
52
3
0
0
0
0
203
0
57
0
0
0
0
87
51
8
0
0
0
0
IoS, Kolkatta
113
0
26
0
18
0
0
35
33
0
1
0
0
0
167
0
54
0
0
0
0
39
53
17
3
0
1
0
CRI, Kasauli
35
0
5
0
7
0
0
11
12
0
0
0
0
0
21
0
11
0
0
0
0
6
4
0
0
0
0
0
1 443
0
347
0
195
1
0
442
384
37
37
0
0
0
1 245
0
375
0
0
0
0
398
338
88
44
0
2
0
18
0
9
0
3
0
0
1
5
0
0
0
0
0
2
0
0
0
0
0
0
2
0
0
0
0
0
0
India Total
Bio Farma, Bandung
Indonesia
0
Negative
0
1
Results
pending
NEV
0
0
Vaccine
3
0
Wild
0
0
VDPV
8
1
Vaccine
IPH, Dhaka
NIH, Bangkok
Wild
Bangladesh
Bhutan
Vaccine
7
Days days
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
Wild
Results
pending
AFP cases
referred
for ITD
NEV
Negative
2017
Vaccine
mixture
NPEV by
PCR
Vaccine
Wild
VDPV
Vaccine
Wild
Vaccine
ITD Labs
Wild
Country of
Case
AFP cases
referred
for ITD
2016
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
NIHRD, Jakarta
12
0
4
0
0
0
0
5
3
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
PHL, Surabaya
13
0
2
0
4
0
0
4
3
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
Indonesia Total
43
0
15
0
7
0
0
10
11
0
0
0
0
0
4
0
0
0
0
0
0
3
1
0
0
0
0
0
Myanm ar
NHL, Yangon
7
0
1
0
1
0
0
2
3
0
0
0
0
0
5
0
1
0
0
0
0
3
1
0
0
0
0
0
Nepal
NIH, Bangkok
6
0
2
0
2
0
0
1
1
0
0
0
0
0
5
0
0
0
0
0
0
3
2
0
0
0
0
0
Sri Lanka
MRI, Colombo
1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
Thailand
NIH, Bangkok
4
0
0
0
0
0
0
2
2
0
0
0
0
0
5
0
2
0
0
0
0
3
0
0
0
0
0
0
1 513
0
368
0
206
1
0
459
404
37
37
1
0
0
1 283
0
386
0
0
0
0
416
347
88
44
0
2
0
TOTAL